Skip to main content
. 2010 Nov 21;17(1):58–65. doi: 10.1111/j.1755-5949.2010.00211.x

Figure 4.

Figure 4

Current therapeutics, unmet clinical needs and therapeutic role of 5‐HT1A receptors in the treatment of Parkinson's disease. AADCI, aromatic L‐amino acid decarboxylase inhibitors; ACh, acetylcholine; MAO‐B, monoamine oxidase‐B; COMT, catechol‐O‐methyltransferase.